Revvity reported third-quarter 2026 results and raised its full-year guidance. It also presented pro forma financial statements reflecting a planned sale of substantially all assets in its China immunodiagnostics business, a transaction management expects to close by the end of 2027.
Key details
- Revenue: Revvity reported revenue of $729 million. Pro forma revenue was $710 million, with 7% pro forma growth and 7% pro forma organic growth.
- Earnings from continuing operations: GAAP earnings per share were $0.56; adjusted EPS was $1.38. On a pro forma basis, GAAP EPS was $0.60 and adjusted EPS was $1.37.
- Full-year outlook: The company said it had raised its full-year guidance. The guidance figures were not included in the available announcement details.
- Planned China business sale: Revvity signed a definitive agreement on July 31, 2026, to sell substantially all assets related to its China immunodiagnostics business. The sale price could be up to $200 million, subject to adjustments and conditions.
- Timing and presentation: Management considers the sale probable and expects it to close by the end of 2027. Revvity’s pro forma financial statements show the company’s financial position and results as if the sale were reflected.
The transaction remains subject to conditions, and the stated price is a maximum rather than a confirmed final amount. The pro forma results give investors a view of Revvity’s financials after accounting for the expected divestiture.